GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Shiller PE Ratio

Protalix BioTherapeutics (Protalix BioTherapeutics) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protalix BioTherapeutics Shiller PE Ratio Historical Data

The historical data trend for Protalix BioTherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Shiller PE Ratio Chart

Protalix BioTherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Protalix BioTherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Protalix BioTherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Protalix BioTherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Shiller PE Ratio falls into.



Protalix BioTherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Protalix BioTherapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Protalix BioTherapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.1/129.4194*129.4194
=-0.100

Current CPI (Dec. 2023) = 129.4194.

Protalix BioTherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.800 99.695 -1.039
201406 -0.700 100.560 -0.901
201409 -0.900 100.428 -1.160
201412 -0.900 99.070 -1.176
201503 -0.600 99.621 -0.779
201506 -0.500 100.684 -0.643
201509 -0.400 100.392 -0.516
201512 7.700 99.792 9.986
201603 -0.900 100.470 -1.159
201606 -1.100 101.688 -1.400
201609 -0.700 101.861 -0.889
201612 -0.200 101.863 -0.254
201703 -4.800 102.862 -6.039
201706 -0.600 103.349 -0.751
201709 -0.900 104.136 -1.119
201712 -0.870 104.011 -1.083
201803 -0.500 105.290 -0.615
201806 -0.600 106.317 -0.730
201809 -0.400 106.507 -0.486
201812 -0.400 105.998 -0.488
201903 -0.500 107.251 -0.603
201906 -0.520 108.070 -0.623
201909 -0.240 108.329 -0.287
201912 0.020 108.420 0.024
202003 0.100 108.902 0.119
202006 -0.130 108.767 -0.155
202009 -0.140 109.815 -0.165
202012 0.030 109.897 0.035
202103 -0.140 111.754 -0.162
202106 -0.250 114.631 -0.282
202109 -0.090 115.734 -0.101
202112 -0.140 117.630 -0.154
202203 -0.050 121.301 -0.053
202206 -0.110 125.017 -0.114
202209 -0.070 125.227 -0.072
202212 -0.070 125.222 -0.072
202303 -0.050 127.348 -0.051
202306 0.210 128.729 0.211
202309 -0.040 129.860 -0.040
202312 -0.100 129.419 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protalix BioTherapeutics  (AMEX:PLX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Protalix BioTherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Executives
Dror Bashan director, officer: President and CEO 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben director 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin officer: Sr. VP and CFO C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos officer: Sr. VP, Operations 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon officer: Vice President, R&D 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld director 6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot director 6225 NEIL ROAD, RENO NV 89511
Pol F Boudes director C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor officer: President & CEO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100